Axiom Investment Management’s CytoMed Therapeutics GDTC Stock Holding History

Axiom Investment Management’s Portfolio GDTC Stock Details GDTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.24K	Buy	+7,032	New	+$7.3K	﹤0.01%	379

Other funds holding GDTC

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Axiom Investment Management's GDTC Position: Q2 2026 in Review

Axiom Investment Management opened a new position in CytoMed Therapeutics (GDTC) in Q2 2026: 7,032 shares worth $7.24K. The stake represents ﹤0.01% of the portfolio and ranks #379 among its holdings.

3 funds tracked by Wall St. Rank hold GDTC as of Q2 2026.

Axiom Investment Management held 7,032 shares of CytoMed Therapeutics worth $7.24K as of Q2 2026.
CytoMed Therapeutics was a new Axiom Investment Management position in Q2 2026.
CytoMed Therapeutics made up ﹤0.01% of Axiom Investment Management's portfolio in Q2 2026, its #379 holding.
3 funds tracked by Wall St. Rank held CytoMed Therapeutics as of Q2 2026.

Based on Axiom Investment Management's 13F filing for Q2 2026, filed 31 Jul 2026.